From CNBC: 2024-04-09 14:42:47

Two cell therapies from Bristol Myers Squibb and Johnson & Johnson received FDA approval as earlier treatment options for multiple myeloma, a type of blood cancer. J&J’s Carvykti has an edge over Bristol Myers’s Abecma, as it can be used after just one prior treatment line. New approvals will benefit thousands of patients. J&J’s Carvykti expected to capture majority of the CAR-T market share in multiple myeloma, potentially reaching over 80,000 patients in the U.S., EU and Japan. Bristol Myers’s Abecma peak sales estimated at $450 million per year. Both companies aim to address supply constraints for their drugs. Mount Sinai Health System is exploring generative AI applications in patient care, education, and research to speed up decision making for clinicians and improve workflows. Radiologists at Mount Sinai are already using AI tools for mammograms, ultrasounds, and image quality evaluations, enhancing confidence in diagnoses. The health system is taking a measured approach to AI implementation, focusing on real problem-solving applications rather than just algorithms.



Read more at CNBC: J&J cell therapy gains edge over Bristol Myers rival